Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
University Health Network, Toronto
Washington University School of Medicine
Takeda
University Hospital, Essen
Eastern Cooperative Oncology Group
Stanford University
Beth Israel Medical Center